Prognostic Factors of Patients With Metastatic Renal Cell Carcinoma With Removed Metastases: A Multicenter Study of 556 Patients

被引:45
作者
Naito, Sei
Kinoshita, Hidefumi
Kondo, Tsunenori
Shinohara, Nobuo
Kasahara, Takashi
Saito, Kazutaka
Takayama, Tatsuya
Masumori, Naoya
Takahashi, Wataru
Takahashi, Masayuki
Terachi, Toshiro
Ozono, Seiichiro
Naito, Seiji
Tomita, Yoshihiko [1 ]
机构
[1] Yamagata Univ, Fac Med, Dept Urol, Yamagata 990, Japan
关键词
INTERFERON-ALPHA; SURVIVAL; THERAPY;
D O I
10.1016/j.urology.2013.06.035
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the prognosis and prognostic factors of patients with metastatic renal cell carcinoma who underwent metastasectomy. METHODS We sent questionnaires to Japanese hospitals. The questionnaires included data of patients with metastatic renal cell carcinoma who had their metastatic lesions removed between January 1988 and December 2009. We collected them and retrospectively analyzed these data and calculated the overall survival from the first metastasectomy until death or last follow-up. We also analyzed the relationship between survival and clinico-pathologic features and determined adverse prognostic factors. Furthermore, we identified a poor prognostic group by counting the number of prognostic factors. RESULTS A sample size of 556 patients from 48 institutions was studied. The median overall survival was 80 months. Four adverse prognostic factors were detected: incomplete resection by metastasectomy (hazard ratio [HR], 2.15), brain metastasis (HR, 3.73), >1.0 mg/dL C-reactive protein (HR, 2.45), and the highest histologic grade in Japanese classification (nuclei of tumor cells are larger than nuclei of normal tubular cells; HR, 1.88). The median overall survivals of patients with 3 or 4 prognostic factors, 2 factors, and 0 and 1 factors were 10 months, 42 months, and 105 months, respectively. CONCLUSION Four adverse prognostic factors for predicting the survival of patients with removed metastases were identified. Patients with 3 or 4 of these adverse prognostic factors had a worse prognosis. UROLOGY 82: 846-851, 2013. (C) 2013 Elsevier Inc.
引用
收藏
页码:846 / 851
页数:6
相关论文
共 22 条
[1]   Survival After Complete Surgical Resection of Multiple Metastases From Renal Cell Carcinoma [J].
Alt, Angela L. ;
Boorjian, Stephen A. ;
Lohse, Christine M. ;
Costello, Brian A. ;
Leibovich, Bradley C. ;
Blute, Michael L. .
CANCER, 2011, 117 (13) :2873-2882
[2]  
Association JU, 2011, GEN RUL CLIN PATH ST
[3]   Adenocarcinoma of the kidney with metastasis to the lung - Cured by nephrectomy and lobectomy [J].
Barney, JD ;
Churchill, EJ .
JOURNAL OF UROLOGY, 1939, 42 (03) :269-276
[4]  
Bukowski RM, 1997, CANCER-AM CANCER SOC, V80, P1198, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO
[5]  
2-H
[6]   Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma [J].
Daliani, Danai D. ;
Tannir, Nizar M. ;
Papandreou, Christos N. ;
Wang, Xuemei ;
Swisher, Stephen ;
Wood, Christopher G. ;
Swanson, David A. ;
Logothetis, Christopher J. ;
Jonasch, Eric .
BJU INTERNATIONAL, 2009, 104 (04) :456-460
[7]   Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma [J].
Eggener, Scott E. ;
Yossepowitch, Ofer ;
Kundu, Shilajit ;
Motzer, Robert J. ;
Russo, Paul .
JOURNAL OF UROLOGY, 2008, 180 (03) :873-878
[8]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917
[9]   PROGNOSTIC-SIGNIFICANCE OF MORPHOLOGIC PARAMETERS IN RENAL-CELL CARCINOMA [J].
FUHRMAN, SA ;
LASKY, LC ;
LIMAS, C .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1982, 6 (07) :655-663
[10]   RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY [J].
FYFE, G ;
FISHER, RI ;
ROSENBERG, SA ;
SZNOL, M ;
PARKINSON, DR ;
LOUIE, AC .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :688-696